{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:02Z","timestamp":1777934522892,"version":"3.51.4"},"reference-count":12,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Lenalidomide is an immunomodulatory agent with multiple mechanisms of action, and treatment with lenalidomide is associated with adverse events such as thrombosis and abdominal pain; nonetheless, other rarer adverse events do exist, with few knowledge from physicians and pharmacists. For such adverse events, pharmacovigilance databases are of great interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>A 71-year-old patient with no rheumatologic history, in complete remission of a mantle-cell lymphoma following rituximab, doxorubicin, vincristine, cyclophosphamide, and prednisone induction, received a maintenance treatment with rituximab and lenalidomide. After each course of lenalidomide and with no other new medication, the patient presented with fever and high inflammatory markers level, and a scapular-belt arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>The patient was managed with non-steroidal anti-inflammatory drugs and colchicine, with symptomatology and inflammation improvement. After discontinuation of lenalidomide, he had no arthritis relapse; it was then concluded that the patient had a lenalidomide-induced arthritis. We interrogated the national and international (VigiBase\u00ae) pharmacovigilance databases and found that arthritis in the context of lenalidomide exposure is a rare finding, with only three reported cases in France; 0.13% of adverse events reported with lenalidomide in the international database VigiBase\u00ae were arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our case then reports an uncommon finding, of which both pharmacists and physicians should be aware due to the wide and increasing use of lenalidomide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211038001","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T07:33:24Z","timestamp":1632987204000},"page":"453-456","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases"],"prefix":"10.1177","volume":"28","author":[{"given":"Charlotte","family":"Icard","sequence":"first","affiliation":[{"name":"Department of Medical and Clinic Pharmacology, CHU de Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7181-3525","authenticated-orcid":false,"given":"Pauline","family":"Mocquot","sequence":"additional","affiliation":[{"name":"Department of Medical and Clinic Pharmacology, CHU de Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Nogaro","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institut Universitaire du Cancer-Oncopole, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Despas","sequence":"additional","affiliation":[{"name":"Department of Medical and Clinic Pharmacology, CHU de Toulouse, France"},{"name":"UMR1027, Inserm, Universit\u00e9 Paul Sabatier, France"},{"name":"Department of Medical and Clinic Pharmacology, Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paul Sabatier, France"},{"name":"Centre Midi-Pyr\u00e9n\u00e9es de Pharmacovigilance, de Pharmaco\u00e9pid\u00e9miologie et d\u2019Informations sur le M\u00e9dicament, Centre Hospitalier Universitaire de Toulouse, France"},{"name":"INSERM CIC 1436 Toulouse, Centre d\u2019Investigation Clinique de Toulouse, Centre Hospitalier Universitaire de Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5338-2071","authenticated-orcid":false,"given":"Martin","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institut Universitaire du Cancer-Oncopole, France"},{"name":"Centre Hospitalier de Cahors, Cahors, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"bibr1-10781552211038001","first-page":"559","volume":"13","author":"Zufferey P","year":"2017","journal-title":"Rev Med Suisse"},{"key":"bibr2-10781552211038001","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064354"},{"key":"bibr3-10781552211038001","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03988-6"},{"key":"bibr4-10781552211038001","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2016.11.005"},{"key":"bibr5-10781552211038001","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2775-y"},{"key":"bibr6-10781552211038001","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15283"},{"key":"bibr7-10781552211038001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"bibr8-10781552211038001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.5229"},{"key":"bibr9-10781552211038001","author":"Martinez-H\u00f8yer S","journal-title":"Exp Hematol"},{"key":"bibr10-10781552211038001","doi-asserted-by":"publisher","DOI":"10.1177\/009286150804200501"},{"key":"bibr11-10781552211038001","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1561865"},{"key":"bibr12-10781552211038001","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.03.009"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211038001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211038001","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211038001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:20Z","timestamp":1777688720000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211038001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1177\/10781552211038001"],"URL":"https:\/\/doi.org\/10.1177\/10781552211038001","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]}}}